Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LB54640 in Healthy Overweight and Obese Subjects
NCT06040372Phase 1Completed
- Sponsor
- LG Chem
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing LB54640 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events (AEs) up to 6 weeks, Incidence and severity of adverse events of special interest (AESIs) up to 6 weeks and 4 more. Started Mar 2020; status: completed.
02
Drugs
LB54640
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06040372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040372.